Amundi Lowers Holdings in BioNTech SE Sponsored ADR $BNTX

Amundi reduced its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 268,337 shares of the company's stock after selling 12,676 shares during the quarter. Amundi owned about 0.11% of BioNTech worth $24,690,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech during the first quarter worth $36,000. Costello Asset Management INC acquired a new stake in shares of BioNTech during the first quarter worth $91,000. Goodman Advisory Group LLC acquired a new stake in shares of BioNTech during the first quarter worth $105,000. Whittier Trust Co. lifted its holdings in shares of BioNTech by 3,846.2% during the first quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after purchasing an additional 2,000 shares during the period. Finally, Probity Advisors Inc. lifted its holdings in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Price Performance

BioNTech stock traded down $7.57 during midday trading on Friday, reaching $96.74. 5,152,296 shares of the company were exchanged, compared to its average volume of 874,805. The company has a market capitalization of $23.26 billion, a price-to-earnings ratio of -60.46 and a beta of 1.39. The firm's 50-day simple moving average is $108.79 and its 200-day simple moving average is $103.98. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. On average, analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several research analyst reports. JPMorgan Chase & Co. cut their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. HC Wainwright reiterated a "buy" rating and issued a $136.00 price objective on shares of BioNTech in a research report on Monday, September 8th. Finally, Morgan Stanley raised their price target on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Thirteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.80.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.